Hydrophilic Ointment RS-200

Compounding pharmacies receive RS-200 as a preserved oil-in-water emulsion vehicle in sealed bulk containers and perform nonsterile levigation of corticosteroid and immunomodulator powders directly into the base. The compendial Hydrophilic Ointment model contains 0.25% w/w methylparaben, 0.15% w/w propylparaben, 1% w/w sodium lauryl sulfate, 12% w/w propylene glycol, 25% w/w stearyl alcohol, 25% w/w white petrolatum and 37% w/w purified water, which means the vehicle already carries an anionic emulsifier and a preserved aqueous phase before any active is added. The API is first wetted with approximately 5% w/w of the total vehicle on a glass ointment slab or in a disposable unguator jar; the remainder is then incorporated in three increasing portions by geometric dilution to avoid localized preservative depletion and uneven distribution. Hydrocortisone is incorporated at 1% w/w or 2.5% w/w, betamethasone valerate at 0.1% w/w, and triamcinolone acetonide at 0.1% w/w in this application. For batch sizes below 500 g, a programmable unguator operated at 600 rpm to 1,200 rpm for 2 to 4 minutes is used; for batches above 1 kg, a three-roll mill with gap settings between 5 µm and 15 µm is preferred to reduce micronized API agglomerates. The product is not heated above 40°C because reheating can partially disrupt the stearyl alcohol network and reduce the yield stress needed for tractable ointment work, although published data for RS-200 heat cycling is limited. After mixing, a sample is evaluated for pH in a 1:1 deionized water dispersion, for coarse particles under a light microscope at 400× magnification, and for preservative effectiveness under USP General Chapter 51. Finished preparations are assigned a beyond-use date under USP General Chapter 795 according to the water-containing semisolid category and the package type; terminal packages include 15 g, 30 g and 60 g polypropylene ointment jars and aluminum tubes filled by positive-displacement equipment. Strongly cationic APIs may interact with the anionic emulsifier and require a pilot compatibility screen before batch execution, so this base is not automatically interchangeable with neutral or nonionic vehicles for every prescription.

What Limits the Zinc Oxide Addition Ratio in RS-200 When Used as an OTC Skin Protectant Base?

For OTC skin protectant compounding, zinc oxide can be dispersed in RS-200 at 20% w/w to produce a final ointment within the zinc oxide concentration range of 1% to 25% w/w established by 21 CFR Part 347. The addition is not a simple tank-mix operation because zinc oxide raises yield stress and requires a predispersion step before the base is transferred to filling equipment. A rotor-stator inline mixer with recirculation at 1,000 rpm to 3,000 rpm wets the powder into the base; the batch then passes at least twice through a three-roll mill to reach a fineness of grind suitable for skin application, checked with ASTM D1210. Because RS-200 already contains 25% w/w white petrolatum, adding zinc oxide increases the occlusive character of the finished ointment and lowers the osmotically active water fraction, which can shift the methylparaben and propylparaben distribution toward the organic phase. Preservative efficacy must therefore be demonstrated under USP General Chapter 51 on the final formulation rather than assumed from the base vehicle alone. Viscosity is measured with a Brookfield T-bar spindle at 5 rpm to generate a lot-specific consistency value; the acceptance range must be tied to the filling line, because a high-yield-stress batch can interrupt positive-displacement tube filling at 30 tubes per minute to 60 tubes per minute. The terminal products are labeled skin protectant ointments for minor irritation, chafing and diaper-area use; the manufacturer verifies room-temperature stability at 25°C ± 2°C and 60% RH ± 5% for the assigned shelf life. Zinc oxide also adsorbs residual free water, so the mill passes are scheduled immediately after predispersion to prevent the batch from gaining consistency during holding.

If a Hospital Pharmacy Standardizes Unit-of-Use Dermatological Packs, Preservative Challenge Becomes the Primary Control

Hospital pharmacies standardizing RS-200 for unit-of-use dermatological packs operate under USP General Chapter 795 and generally limit batch size to 50 g to 500 g so that the entire batch can be assigned to patient-specific orders or a single clinic stock. Triamcinolone acetonide is dispersed at 0.1% w/w in most default protocols, while mupirocin calcium is incorporated at 2% w/w only after a compatibility check because published data for this specific configuration is limited and the anionic emulsifier can affect charged actives. The mixing program uses a disposable unguator blade at 800 rpm to 1,200 rpm for 2 minutes, followed by vacuum deaeration at −0.08 MPa for 60 seconds to prevent air bubbles from creating underfilled tubes during net-weight filling. The critical quality gate in hospital practice is the preservative effectiveness test under USP General Chapter 51 rather than a comprehensive cGMP stability protocol; if a batch fails that challenge, it cannot receive a beyond-use date beyond the immediate-use window and is discarded at the end of the hospital shift. Terminal packages are 5 g or 10 g foil-lined ointment jars and amber tubes with tamper-evident caps, labeled with the patient identifier, control number and compounding record number. High-volume hospital fleets often standardize a single fill weight and a single jar size to reduce the number of package-level verification checks required during pharmacy dispensing.

Clinical Trial Vehicle Manufacture Under Annex 13 Blinding Constraints

For phase 2 and phase 3 investigational topical ointments, contract manufacturing organizations use RS-200 as a preserved placebo vehicle and as the active-arm base when a clinical protocol requires a visually identical oil-in-water semisolid with moderate occlusivity. The API addition ratio is protocol-specific: betamethasone valerate is incorporated at 0.1% w/w in the active arm, while the placebo arm contains 0% w/w API and is processed through the same vacuum planetary mixer to maintain identical microstructure. Manufacture follows 21 CFR Part 211 for investigational medicinal products and, where EU release is required, EudraLex Volume 4 Annex 13; batch records document the sequential addition of the active, vacuum mixing parameters and in-process fill weight verification. The mixing vessel is typically a vacuum planetary mixer with independently controlled planetary and disperser blades; the disperser is operated in short pulses rather than continuously to avoid over-shearing the stearyl alcohol network, and the batch is deaerated at −0.08 MPa before transfer to the hopper. Filling is performed on a positive-displacement tube filler with a checkweigher controlling 2.0 g ± 0.1 g per tube; because the product is opaque, tamper-evident aluminum tubes are used and labeled with cGMP production records, randomization numbers and storage statements. RS-200 contains methylparaben and propylparaben, so it is unsuitable for clinical protocols requiring a paraben-free vehicle, and the sponsor must confirm that the vehicle composition matches the investigational medicinal product dossier. The terminal product type is a double-blinded investigational topical ointment or placebo unit for phase 1, phase 2 or phase 3 dermatology trials.

Veterinary Dermatological Labels Require AMDUCA Overlay Despite Identical Base Composition

In companion-animal compounding, RS-200 is used as the base for veterinary dermatological prescriptions when the veterinarian requests a nonsterile, preserved ointment with lower solvent drag than polyethylene glycol vehicle. Tacrolimus is incorporated at 0.03% w/w to 0.1% w/w for localized feline or canine dermatitis in compounded formulations, but the animal species, body weight and lesion location must be recorded in the pharmacy log because RS-200 is not a registered veterinary drug product and its use in animals is extralabel. The regulatory overlay is provided by 21 CFR Part 530 under the Animal Medicinal Drug Use Clarification Act; a valid veterinarian-client-patient relationship is required, and food-producing animal use is excluded from this application because the base and many actives are not evaluated for tissue residues. The downstream process uses slab levigation or a disposable unguator at 600 rpm to 1,200 rpm for 2 to 4 minutes, but the filling operation is configured for 5 g to 30 g amber ointment jars with child-resistant closures and auxiliary labels that include the species-specific statement “not for use in food-producing animals.” The propylene glycol content of RS-200 also requires species-specific review because propylene glycol is not universally preferred in feline patients, so the veterinarian is responsible for confirming appropriateness before dispensing. The terminal product is a veterinary labeled compounded ointment; if the API has not been evaluated for stability in this base, the pharmacy assigns the shortest beyond-use date category under USP General Chapter 795 and limits the batch to a single patient or small clinic stock to minimize risk from an unvalidated combination.

Establishing In Vitro Release Controls for RS-200 as a Semi-Solid Reference Vehicle

When RS-200 is evaluated as a reference matrix for in vitro release testing and in vitro permeation testing, analytical laboratories use the vehicle at 100% w/w as the control or load it with a known active concentration such as 0.05% w/w hydrocortisone to qualify the composition against USP General Chapter 1724. The preparation is performed under laboratory-scale vacuum mixing to remove entrapped air that would otherwise create artificial diffusion resistance in Franz diffusion cells; donor chambers are filled with 300 mg to 500 mg of the semisolid per cell, and receptor chambers contain phosphate-buffered saline or an alternative receptor medium selected for sink conditions. The diffusion cells are equilibrated in a water bath at 32°C for 30 minutes before sampling to stabilize the membrane boundary layer and to remove residual air pockets. Compliance with the performance chapter is documented by recording the flux profile and the coefficient of variation across six diffusion cells; acceptance limits are method-specific and must be validated in the laboratory, and published data for this specific configuration is limited, so no pre-existing limits can be substituted for analytical validation. The terminal output is not a finished patient product but an analytical reference standard or vehicle control used to support in vitro release characterization and bioequivalence-oriented method development.